Sarepta Therapeutics (SRPT) Leases (2019 - 2025)
Historic Leases for Sarepta Therapeutics (SRPT) over the last 8 years, with Q3 2025 value amounting to $139.2 million.
- Sarepta Therapeutics' Leases fell 122.85% to $139.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.2 million, marking a year-over-year decrease of 122.85%. This contributed to the annual value of $148.3 million for FY2024, which is 1412.68% up from last year.
- Per Sarepta Therapeutics' latest filing, its Leases stood at $139.2 million for Q3 2025, which was down 122.85% from $143.0 million recorded in Q2 2025.
- Sarepta Therapeutics' 5-year Leases high stood at $148.3 million for Q4 2024, and its period low was $43.0 million during Q3 2022.
- Its 5-year average for Leases is $99.3 million, with a median of $124.0 million in 2024.
- As far as peak fluctuations go, Sarepta Therapeutics' Leases tumbled by 5038.09% in 2021, and later soared by 21011.29% in 2023.
- Quarter analysis of 5 years shows Sarepta Therapeutics' Leases stood at $45.5 million in 2021, then surged by 42.66% to $65.0 million in 2022, then surged by 100.07% to $130.0 million in 2023, then increased by 14.13% to $148.3 million in 2024, then fell by 6.16% to $139.2 million in 2025.
- Its Leases was $139.2 million in Q3 2025, compared to $143.0 million in Q2 2025 and $147.1 million in Q1 2025.